Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.881277
Corrigendum: A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages
- 1Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- 2Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China
- 3Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- 4Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University, Nanjing, China
A Corrigendum on
A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages
By Zhang J, Jiang P, Sheng L, Liu Y, Liu Y, Li M, Tao M, Hu L, Wang X, Yang Y, Xu Y and Liu W (2021). Front. Immunol. 12:609615. doi: 10.3389/fimmu.2021.609615
In the original article, there was a mistake in Figure 1 as published. In Figure 1A, the y-axis of the top graph was labelled “CD68 staining score”, when it should have been labelled “TLR2 staining score”. The corrected Figure 1 appears below.
Figure 1 Inflammatory cells especially macrophages are abundant in rosacea skin, together with cathelicidin. The skin lesions (n = 5) of individuals with rosacea were biopsied and embedded into wax blocks. (A) Profound accumulation of inflammatory cells can be observed in the skin samples stained by HE. The pictures were taken under ×100, ×200, and ×400 magnification. (B) TLR2, KLK5, and cathelicidin are abundant in lesional skin of individuals with rosacea as detected by immunochemical staining; the pictures were taken under ×200 magnification. (C) Macrophages in lesional skin of individuals with rosacea as examined by immunohistochemistry with an antibody against CD68, and inflammatory reactions determined by staining with antibodies against TNF-α and IL-1 β. The pictures were taken under ×200 magnification; ***P <0.001 (n = 5).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: rosacea, carvedilol, macrophage, TLR2, KLK5, cathelicidin
Citation: Zhang J, Jiang P, Sheng L, Liu Y, Liu Y, Li M, Tao M, Hu L, Wang X, Yang Y, Xu Y and Liu W (2022) Corrigendum: A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages. Front. Immunol. 13:881277. doi: 10.3389/fimmu.2022.881277
Received: 22 February 2022; Accepted: 28 February 2022;
Published: 14 March 2022.
Edited and reviewed by:Jingyuan Wan, Chongqing Medical University, China
Copyright © 2022 Zhang, Jiang, Sheng, Liu, Liu, Li, Tao, Hu, Wang, Yang, Xu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yang Xu, firstname.lastname@example.org; Wentao Liu, email@example.com
†These authors have contributed equally to this work